ALK-Abelló Acquires Allerbio
| ALK-abelló enters the French immunotherapy market. |
| ALK-Abelló A/S and French Allerbio S.A. have entered into an agreement by which ALK-Abelló will buy 100% of the share capital of Allerbio.
The agreement represents an important step forward in ALK-Abelló's strategy to be present in the important French market, the second largest immunotherapy market in Europe. ALK-Abelló A/S is the world-leading producer of pharmaceuticals for specific allergy vaccination. The company focuses on curing respiratory allergy and on transforming allergy treatment through the continuous development of more effective and patient-friendly products. Specifically, Grazax, the first tablet-based vaccine against grass pollen allergy, is currently pending registration with the Swedish authorities and a European launch is expected by the end of 2006. For further information please contact: Jens Bager, President and CEO Tel: +45 45 74 74 45 Email: mailbox@dk.alk-abello.com |
| Related links: www.alk-abello.com |